Upfront Treatment of FLT3-Mutated AML: A Look Back at the RATIFY Trial and Beyond

Overview

Journal Front Oncol

Specialty Oncology

Date 2021 Jan 8

PMID 33415071

Citations 4

Authors

Gina Keiffer

Kimberly L Aderhold

Neil D Palmisiano

Affiliations

Soon will be listed here.

Citing Articles

[Clinical study of induction chemotherapy followed by allogeneic hematopoietic stem cell transplantation in the treatment of FLT3-ITD(+) acute myeloid leukemia with normal karyotype].

Li F, Liu Y, Zhu H, Hong M, Qian S, Zhu Y Zhonghua Xue Ye Xue Za Zhi. 2023; 44(3):230-235.

PMID: 37356985 PMC: 10119728. DOI: 10.3760/cma.j.issn.0253-2727.2023.03.009.

The clinical impact of the molecular landscape of acute myeloid leukemia.

Kayser S, Levis M Haematologica. 2023; 108(2):308-320.

PMID: 36722402 PMC: 9890016. DOI: 10.3324/haematol.2022.280801.

Advancements on the Multifaceted Roles of Sphingolipids in Hematological Malignancies.

Raza Y, Atallah J, Luberto C Int J Mol Sci. 2022; 23(21).

PMID: 36361536 PMC: 9654982. DOI: 10.3390/ijms232112745.

In Pursuit of Genetic Prognostic Factors and Treatment Approaches in Secondary Acute Myeloid Leukemia-A Narrative Review of Current Knowledge.

Stefaniuk P, Szymczyk A, Podhorecka M J Clin Med. 2022; 11(15).

PMID: 35893374 PMC: 9332027. DOI: 10.3390/jcm11154283.

References

Antar A, Otrock Z, Jabbour E, Mohty M, Bazarbachi A . FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions. Leukemia. 2020; 34(3):682-696. DOI: 10.1038/s41375-019-0694-3. View

Ambinder A, Levis M . Potential targeting of FLT3 acute myeloid leukemia. Haematologica. 2020; 106(3):671-681. PMC: 7927884. DOI: 10.3324/haematol.2019.240754. View

Williams A, Nguyen B, Li L, Brown P, Levis M, Leahy D . Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors. Leukemia. 2012; 27(1):48-55. PMC: 3822911. DOI: 10.1038/leu.2012.191. View

Altman J, Foran J, Pratz K, Trone D, Cortes J, Tallman M . Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia. Am J Hematol. 2017; 93(2):213-221. PMC: 6586071. DOI: 10.1002/ajh.24974. View

Jan M, Snyder T, Corces-Zimmerman M, Vyas P, Weissman I, Quake S . Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia. Sci Transl Med. 2012; 4(149):149ra118. PMC: 4045621. DOI: 10.1126/scitranslmed.3004315. View

Perl A, Martinelli G, Cortes J, Neubauer A, Berman E, Paolini S . Gilteritinib or Chemotherapy for Relapsed or Refractory -Mutated AML. N Engl J Med. 2019; 381(18):1728-1740. DOI: 10.1056/NEJMoa1902688. View

Stone R . What FLT3 inhibitor holds the greatest promise?. Best Pract Res Clin Haematol. 2018; 31(4):401-404. DOI: 10.1016/j.beha.2018.09.008. View

Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum F, Buchner T . Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2016; 129(4):424-447. PMC: 5291965. DOI: 10.1182/blood-2016-08-733196. View

Albers C, Leischner H, Verbeek M, Yu C, Illert A, Peschel C . The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013; 27(6):1416-8. DOI: 10.1038/leu.2013.14. View

10.

Kottaridis P, Gale R, Frew M, Harrison G, Langabeer S, BELTON A . The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the.... Blood. 2001; 98(6):1752-9. DOI: 10.1182/blood.v98.6.1752. View

11.

Pratz K, Sato T, Murphy K, Stine A, Rajkhowa T, Levis M . FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML. Blood. 2009; 115(7):1425-32. PMC: 2826764. DOI: 10.1182/blood-2009-09-242859. View

12.

Kazi J, Ronnstrand L . FMS-like Tyrosine Kinase 3/FLT3: From Basic Science to Clinical Implications. Physiol Rev. 2019; 99(3):1433-1466. DOI: 10.1152/physrev.00029.2018. View

13.

Patel J, Gonen M, Figueroa M, Fernandez H, Sun Z, Racevskis J . Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012; 366(12):1079-89. PMC: 3545649. DOI: 10.1056/NEJMoa1112304. View

14.

Perl A . Availability of FLT3 inhibitors: how do we use them?. Blood. 2019; 134(9):741-745. DOI: 10.1182/blood.2019876821. View

15.

Fischer T, Stone R, DeAngelo D, Galinsky I, Estey E, Lanza C . Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. J Clin Oncol. 2010; 28(28):4339-45. PMC: 4135183. DOI: 10.1200/JCO.2010.28.9678. View

16.

Frohling S, Schlenk R, Breitruck J, Benner A, Kreitmeier S, Tobis K . Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood. 2002; 100(13):4372-80. DOI: 10.1182/blood-2002-05-1440. View

17.

Schnittger S, Schoch C, Dugas M, Kern W, Staib P, Wuchter C . Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood. 2002; 100(1):59-66. DOI: 10.1182/blood.v100.1.59. View

18.

Stone R, Mandrekar S, Sanford B, Laumann K, Geyer S, Bloomfield C . Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. N Engl J Med. 2017; 377(5):454-464. PMC: 5754190. DOI: 10.1056/NEJMoa1614359. View

19.

Weis T, Marini B, Bixby D, Perissinotti A . Clinical considerations for the use of FLT3 inhibitors in acute myeloid leukemia. Crit Rev Oncol Hematol. 2019; 141:125-138. DOI: 10.1016/j.critrevonc.2019.06.011. View